590 related articles for article (PubMed ID: 25044127)
21. Responses of renal hemodynamics and tubular functions to acute sodium-glucose cotransporter 2 inhibitor administration in non-diabetic anesthetized rats.
Ansary TM; Fujisawa Y; Rahman A; Nakano D; Hitomi H; Kobara H; Masaki T; Titze JM; Kitada K; Nishiyama A
Sci Rep; 2017 Aug; 7(1):9555. PubMed ID: 28842583
[TBL] [Abstract][Full Text] [Related]
22. Failure to confirm a sodium-glucose cotransporter 2 inhibitor-induced hematopoietic effect in non-diabetic rats with renal anemia.
Yamazaki D; Konishi Y; Morikawa T; Kobara H; Masaki T; Hitomi H; Osafune K; Nakano D; Kittikulsuth W; Nishiyama A
J Diabetes Investig; 2020 Jul; 11(4):834-843. PubMed ID: 31880858
[TBL] [Abstract][Full Text] [Related]
23. Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells.
Maki T; Maeno S; Maeda Y; Yamato M; Sonoda N; Ogawa Y; Wakisaka M; Inoguchi T
Sci Rep; 2019 Mar; 9(1):4703. PubMed ID: 30886225
[TBL] [Abstract][Full Text] [Related]
24. Two novel homozygous SLC2A9 mutations cause renal hypouricemia type 2.
Dinour D; Gray NK; Ganon L; Knox AJ; Shalev H; Sela BA; Campbell S; Sawyer L; Shu X; Valsamidou E; Landau D; Wright AF; Holtzman EJ
Nephrol Dial Transplant; 2012 Mar; 27(3):1035-41. PubMed ID: 21810765
[TBL] [Abstract][Full Text] [Related]
25. Sodium-Glucose Cotransporter-2 Inhibitor Immediately Decreases Serum Uric Acid Levels in Type 2 Diabetic Patients.
Ohashi N; Aoki T; Matsuyama T; Ishigaki S; Isobe S; Fujikura T; Hashimoto T; Tsuriya D; Morita H; Kato A; Yasuda H
Med Sci Monit; 2020 Oct; 26():e926086. PubMed ID: 33004785
[TBL] [Abstract][Full Text] [Related]
26. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose.
Kanai Y; Lee WS; You G; Brown D; Hediger MA
J Clin Invest; 1994 Jan; 93(1):397-404. PubMed ID: 8282810
[TBL] [Abstract][Full Text] [Related]
27. Effect of baseline urinary glucose levels on the relationship between sodium-glucose cotransporter 2 inhibitors and serum uric acid in Japanese patients with type 2 diabetes mellitus.
Tanaka Y; Ota R; Hirata A; Yokoyama S; Nakagawa C; Uno T; Hosomi K
Pharmazie; 2023 Dec; 78(11):238-244. PubMed ID: 38178282
[TBL] [Abstract][Full Text] [Related]
28. Resveratrol, a novel inhibitor of GLUT9, ameliorates liver and kidney injuries in a D-galactose-induced ageing mouse model
Li L; Li Y; Luo J; Jiang Y; Zhao Z; Chen Y; Huang Q; Zhang L; Wu T; Pang J
Food Funct; 2021 Sep; 12(18):8274-8287. PubMed ID: 34180933
[TBL] [Abstract][Full Text] [Related]
29. In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
Chino Y; Hasegawa M; Fukasawa Y; Mano Y; Bando K; Miyata A; Nakai Y; Endo H; Yamaguchi JI
Xenobiotica; 2017 Apr; 47(4):314-323. PubMed ID: 27324291
[TBL] [Abstract][Full Text] [Related]
30. Luseogliflozin, a SGLT2 Inhibitor, Does Not Affect Glucose Uptake Kinetics in Renal Proximal Tubules of Live Mice.
Zhang A; Nakano D; Kittikulsuth W; Yamashita Y; Nishiyama A
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360935
[TBL] [Abstract][Full Text] [Related]
31. Renal Reabsorptive Transport of Uric Acid Precursor Xanthine by URAT1 and GLUT9.
Arakawa H; Amezawa N; Kawakatsu Y; Tamai I
Biol Pharm Bull; 2020; 43(11):1792-1798. PubMed ID: 33132325
[TBL] [Abstract][Full Text] [Related]
32. Luseogliflozin for the treatment of type 2 diabetes.
Seino Y
Expert Opin Pharmacother; 2014 Dec; 15(18):2741-9. PubMed ID: 25359155
[TBL] [Abstract][Full Text] [Related]
33. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus.
Lytvyn Y; Škrtić M; Yang GK; Yip PM; Perkins BA; Cherney DZ
Am J Physiol Renal Physiol; 2015 Jan; 308(2):F77-83. PubMed ID: 25377916
[TBL] [Abstract][Full Text] [Related]
34. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2.
Ghezzi C; Loo DDF; Wright EM
Diabetologia; 2018 Oct; 61(10):2087-2097. PubMed ID: 30132032
[TBL] [Abstract][Full Text] [Related]
35. Sodium glucose cotransporter 2 and the diabetic kidney.
Komala MG; Panchapakesan U; Pollock C; Mather A
Curr Opin Nephrol Hypertens; 2013 Jan; 22(1):113-9. PubMed ID: 23042029
[TBL] [Abstract][Full Text] [Related]
36. Urate transport capacity of glucose transporter 9 and urate transporter 1 in cartilage chondrocytes.
Zhang B; Duan M; Long B; Zhang B; Wang D; Zhang Y; Chen J; Huang X; Jiao Y; Zhu L; Zeng X
Mol Med Rep; 2019 Aug; 20(2):1645-1654. PubMed ID: 31257523
[TBL] [Abstract][Full Text] [Related]
37. Clinical Predictors of the Hypoglycemic Effect of Sodium-Glucose Co-transporter-2 Inhibitors in Hyperuricemic Patients: A Retrospective Descriptive Observational Study.
Hirai T; Kawagoe Y; Kei M; Ogawa R; Itoh T
Biol Pharm Bull; 2020; 43(5):782-787. PubMed ID: 32378557
[TBL] [Abstract][Full Text] [Related]
38. Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors: no enemy but time?
Pafili K; Papanas N
Expert Opin Pharmacother; 2015 Mar; 16(4):453-6. PubMed ID: 25605060
[TBL] [Abstract][Full Text] [Related]
39. Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II-dependent kidney damage.
Reyes-Pardo H; Bautista R; Vargas-Robles H; Rios A; Sánchez D; Escalante B
BMC Nephrol; 2019 Aug; 20(1):292. PubMed ID: 31375080
[TBL] [Abstract][Full Text] [Related]
40. Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes.
Ferrannini E; Veltkamp SA; Smulders RA; Kadokura T
Diabetes Care; 2013 May; 36(5):1260-5. PubMed ID: 23359360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
